Trial Profile
Distribution of Eosinophils in Asthma After Reslizumab (DEAR). A 7-Week, Placebo-Controlled, Double-Blinded, Parallel-Group, Imaging Study Using Positron Emission Tomography/Computer Tomography (PET/CT) to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation in Patients With Eosinophilic Asthma
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary) ; Fludeoxyglucose F-18
- Indications Asthma
- Focus Therapeutic Use
- Acronyms DEAR
- Sponsors Teva Branded Pharmaceutical Products R&D
- 29 Aug 2018 Status changed from recruiting to discontinued due to Internal business decision.
- 02 Nov 2017 Planned End Date changed from 31 Mar 2019 to 11 May 2019.
- 02 Nov 2017 Planned primary completion date changed from 28 Feb 2019 to 11 Apr 2019.